Oncology Position

Seatbelts and airbags...

 

Merck's current clinical trial activity in this space -
Keynote 629 has 47 sites, only a matter of time before they'll get reimbursement and then you are toasted.

Recruiting Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

• Recurrent Skin Carcinoma
• Skin Squamous Cell Carcinoma

• Biological: Pembrolizumab

• Emory University/Winship Cancer Institute
  Atlanta, Georgia, United States

The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck

• Squamous Cell Carcinoma of the Head and Neck

• Drug: Pembrolizumab
• Radiation: IMRT 60-66Gy

• University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
  Cleveland, Ohio, United States
• Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
  Cleveland, Ohio, United States

Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629)

• Squamous Cell Carcinoma

• Biological: pembrolizumab

• St. Joseph Heritage Healthcare ( Site 0350)
  Santa Rosa, California, United States
• Yale University ( Site 0365)
  New Haven, Connecticut, United States
• Lombardi Comprehensive Cancer Center ( Site 0360)
  Washington, District of Columbia, United States
• (and 44 more...)

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

• HNSCC
• Lip SCC
• Oral Cavity Cancer
• (and 9 more...)

• Drug: Pembrolizumab, Cetuximab

• UCSD Moores Cancer Center
  La Jolla, California, United States

Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors

• Advanced Cancers

• Drug: Pembrolizumab
• Behavioral: Phone Call Follow-Up

• University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

 

Better have some barf bags too if you get on this ride, cause you're gonna be sick.

 

Interesting to see some of the Merck drones apply for the position....why is that? Culture not great or just too many pod mates?

 

BAM! Very nice comeback. Thank you for putting that snotty punk with all his studies and indications and POD MATES in his place.

BTW, after being in immunology BIOLOGIC sales for 15 yrs and actually being passed over twice in the past for Onc jobs because of a lack of Onc experience (it sounds so magical), it's ironic that I actually am more qualified to sell this new wave of therapies than you dried-up chemo reps.

 

Official brand name for REGN2810 announced......Caboose!!!

 

You're not listening, this drug is not going to sell. In this case being qualified is irrelevant.

Perhaps you were actually not passed up for not having onc experience. Perhaps it was just because they didn't like you and your snotty attitude.

 

You have the brand name correct. The generic name is metoovamab.

 

Sounds like RGN is beating the bushes for candidates. Be careful stepping around this pile.

 

Repeat: BETTER MOUSETRAP

 

Yep...there’s a rat in there all right!

 

Run, Forrest, Run!!!

 

If the drug is going to be such a disaster...why are their reps from Merck and BMS applying?

 

Well genius, just like 1/2 of all docs graduate in bottom half of their class “their” are lousy reps....on plans...or have crummy bosses and are DESPERATE to leave. Give them 6-12 months and they’ll be running from “Caboose”/metoovamab to one of the other half dozen pd1’s. BTW when does eylea come off patent? 20 months?

 

BMS and Merck have great drugs but they have too many reps and metrics...sorry places to work! The big pharma companies are stupid enough to believe their consultants that by hiring more reps they will actually increase the frequency they see prescribers...so naive!

 

They are simply not very smart.

 

Are you suggesting they believe this drug is going to be superior to the ones they are currently selling and so they're changing ships? That's hilarious. Thank you, haven't laughed like that in a couple of days.

They work at horrible places and they assume their PD1 experience will give them a leg up in interviews.

 

'Nuff said!

 

Believe it.

 

Like Praulent! LOL.